Home › Trial NCT01716806
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
- Trial IDNCT01716806
- StatusCompleted
- PhasePhase 2
- Study typeInterventional
- SponsorSeagen Inc.
- Enrollment131
- Start date2012-10-31
- ConditionsHodgkin Disease · Peripheral T Cell Lymphoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.